Persistence of IL-17 and TNF inhibitors following initial TNF inhibitor use in axial spondyloarthritis: a nationwide retrospective cohort study
Therapeutic Advances in Musculoskeletal Disease
Published online on February 23, 2026
Abstract
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the axial skeleton, with tumor necrosis factor inhibitors (TNFi) as the standard first-line biologic disease-modifying antirheumatic drugs since the early ...
Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the axial skeleton, with tumor necrosis factor inhibitors (TNFi) as the standard first-line biologic disease-modifying antirheumatic drugs since the early ...